Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.39
BRKR's Cash to Debt is ranked lower than
58% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.62 vs. BRKR: 1.39 )
Ranked among companies with meaningful Cash to Debt only.
BRKR' s Cash to Debt Range Over the Past 10 Years
Min: 0.13  Med: 1.42 Max: N/A
Current: 1.39
Equity to Asset 0.40
BRKR's Equity to Asset is ranked lower than
75% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. BRKR: 0.40 )
Ranked among companies with meaningful Equity to Asset only.
BRKR' s Equity to Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.43 Max: 0.69
Current: 0.4
0.14
0.69
Interest Coverage 13.94
BRKR's Interest Coverage is ranked lower than
62% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.61 vs. BRKR: 13.94 )
Ranked among companies with meaningful Interest Coverage only.
BRKR' s Interest Coverage Range Over the Past 10 Years
Min: 7.92  Med: 12.71 Max: 27.8
Current: 13.94
7.92
27.8
F-Score: 8
Z-Score: 3.94
M-Score: -2.51
WACC vs ROIC
7.78%
23.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.00
BRKR's Operating margin (%) is ranked higher than
70% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.72 vs. BRKR: 10.00 )
Ranked among companies with meaningful Operating margin (%) only.
BRKR' s Operating margin (%) Range Over the Past 10 Years
Min: 5.83  Med: 9.05 Max: 12.27
Current: 10
5.83
12.27
Net-margin (%) 7.21
BRKR's Net-margin (%) is ranked higher than
70% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.29 vs. BRKR: 7.21 )
Ranked among companies with meaningful Net-margin (%) only.
BRKR' s Net-margin (%) Range Over the Past 10 Years
Min: 3.13  Med: 5.68 Max: 7.31
Current: 7.21
3.13
7.31
ROE (%) 16.19
BRKR's ROE (%) is ranked higher than
85% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. BRKR: 16.19 )
Ranked among companies with meaningful ROE (%) only.
BRKR' s ROE (%) Range Over the Past 10 Years
Min: 7.03  Med: 12.65 Max: 22.27
Current: 16.19
7.03
22.27
ROA (%) 6.66
BRKR's ROA (%) is ranked higher than
76% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. BRKR: 6.66 )
Ranked among companies with meaningful ROA (%) only.
BRKR' s ROA (%) Range Over the Past 10 Years
Min: 2.94  Med: 4.85 Max: 7.1
Current: 6.66
2.94
7.1
ROC (Joel Greenblatt) (%) 31.08
BRKR's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -12.38 vs. BRKR: 31.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BRKR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 19  Med: 27.20 Max: 38.5
Current: 31.08
19
38.5
Revenue Growth (3Y)(%) -3.50
BRKR's Revenue Growth (3Y)(%) is ranked lower than
66% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.10 vs. BRKR: -3.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BRKR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 15.40 Max: 27.9
Current: -3.5
0
27.9
EBITDA Growth (3Y)(%) -3.20
BRKR's EBITDA Growth (3Y)(%) is ranked lower than
56% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. BRKR: -3.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BRKR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 7.90 Max: 80.8
Current: -3.2
0
80.8
EPS Growth (3Y)(%) 9.30
BRKR's EPS Growth (3Y)(%) is ranked higher than
68% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. BRKR: 9.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BRKR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 9.30 Max: 113.6
Current: 9.3
0
113.6
» BRKR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

BRKR Guru Trades in Q2 2015

Mariko Gordon 198,875 sh (New)
NWQ Managers 1,843,923 sh (+8.40%)
Vanguard Health Care Fund 4,669,258 sh (unchged)
Murray Stahl 43,955 sh (-3.30%)
Jim Simons 69,710 sh (-69.20%)
Joel Greenblatt 126,102 sh (-86.05%)
Steven Cohen 23,000 sh (-87.78%)
» More
Q3 2015

BRKR Guru Trades in Q3 2015

Ray Dalio 25,806 sh (New)
Mariko Gordon 219,866 sh (+10.55%)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Steven Cohen Sold Out
NWQ Managers 1,820,880 sh (-1.25%)
Murray Stahl 39,774 sh (-9.51%)
Vanguard Health Care Fund 3,821,158 sh (-18.16%)
» More
Q4 2015

BRKR Guru Trades in Q4 2015

George Soros 29,900 sh (New)
Ray Dalio Sold Out
Vanguard Health Care Fund Sold Out
Mariko Gordon 195,199 sh (-11.22%)
Murray Stahl 24,926 sh (-37.33%)
NWQ Managers 631,709 sh (-65.31%)
» More
Q1 2016

BRKR Guru Trades in Q1 2016

Joel Greenblatt 712,459 sh (New)
Paul Tudor Jones 38,748 sh (New)
Jim Simons 441,110 sh (New)
George Soros Sold Out
Murray Stahl 18,535 sh (-25.64%)
NWQ Managers 340,590 sh (-46.08%)
Mariko Gordon 102,527 sh (-47.48%)
» More
» Details

Insider Trades

Latest Guru Trades with BRKR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:ICLR, NAS:VWR, NYSE:CRL, NYSE:BIO, NAS:PRXL, OTCPK:SWTUY, OTCPK:DSRLF, OTCPK:CZMWY, NAS:PRAH, NAS:CPHD, OTCPK:BMXMF, NAS:QGEN, NAS:INCR, NAS:MYGN, NAS:NEOG, OTCPK:ERFSF, NYSE:PKI, NAS:KANG, NAS:EXAS, NAS:AFFX » details
Traded in other countries:BKD.Germany,
Bruker Corp is designer and manufacturer of life science & materials research systems in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology & in-vitro diagnostics industries.

Bruker Corp was incorporated in Delaware and is a designer and manufacturer of proprietary life science and materials research systems and associated products that address the rapidly evolving needs of customers in life science, pharmaceutical, biotechnological, clinical and molecular diagnostics research, and materials and chemical analysis in various industries and government applications. Its technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas chromatography technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology, and infrared and Raman molecular spectroscopy technologies. The Company manufactures and distributes field analytical systems for chemical, biological, radiological, nuclear and explosives, or CBRNE, detection. It also designs, manufactures and markets high and low temperature superconducting materials and devices based on metallic low temperature superconductors. The Company is organized into four operating segments: the Bruker BioSpin Group, the Bruker CALID Group, the Bruker MAT Group, and Bruker Energy & Supercon Technologies division. The Bruker BioSpin Group combines the Bruker Magnetic Resonance and Preclinical Imaging divisions and designs, manufactures and distributes enabling life science tools based on magnetic resonance and preclinical imaging technologies. The Bruker CALID Group combines the Bruker Life Sciences and Clinical, Bruker Chemical and Applied Markets, Bruker Detection and Bruker Optics divisions. It designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as Chemical, Biological, Radiological, Nuclear and Explosive detection products and instruments based on Raman molecular spectroscopy technologies. The Bruker MAT Group combines the Bruker AXS, Bruker Nano Surfaces, Bruker Nano Analytics and Bruker Elemental divisions and designs, manufactures and distributes spectroscopy and microscopy instruments for the analysis of composition and structure in material science and life science samples. The Bruker Energy & Supercon Technologies division develops and produces low temperature superconductor and high temperature superconductor materials for use in magnet technology and energy applications as well as linear accelerators, accelerator cavities, insertion devices, other accelerator components and specialty superconducting magnets for physics and energy research and a variety of other scientific applications. Company maintains direct sales forces throughout North America, Europe, Japan, Asia Pacific and Australia. It also utilizes indirect sales channels to reach customers. It also has various international distributors, independent sales representatives, and various other representatives in parts of Asia, Latin America, and Eastern Europe. Compa

Ratios

vs
industry
vs
history
P/E(ttm) 34.82
BRKR's P/E(ttm) is ranked lower than
57% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.11 vs. BRKR: 34.82 )
Ranked among companies with meaningful P/E(ttm) only.
BRKR' s P/E(ttm) Range Over the Past 10 Years
Min: 7.21  Med: 34.39 Max: 72.5
Current: 34.82
7.21
72.5
Forward P/E 23.53
BRKR's Forward P/E is ranked lower than
64% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.76 vs. BRKR: 23.53 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 34.82
BRKR's PE(NRI) is ranked lower than
57% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.79 vs. BRKR: 34.82 )
Ranked among companies with meaningful PE(NRI) only.
BRKR' s PE(NRI) Range Over the Past 10 Years
Min: 7.21  Med: 34.39 Max: 72.5
Current: 34.82
7.21
72.5
Price/Owner Earnings (ttm) 40.71
BRKR's Price/Owner Earnings (ttm) is ranked lower than
65% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 33.58 vs. BRKR: 40.71 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BRKR' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.85  Med: 45.60 Max: 6933.33
Current: 40.71
10.85
6933.33
P/B 5.65
BRKR's P/B is ranked lower than
74% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.37 vs. BRKR: 5.65 )
Ranked among companies with meaningful P/B only.
BRKR' s P/B Range Over the Past 10 Years
Min: 1.61  Med: 4.20 Max: 8.92
Current: 5.65
1.61
8.92
P/S 2.46
BRKR's P/S is ranked higher than
61% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.37 vs. BRKR: 2.46 )
Ranked among companies with meaningful P/S only.
BRKR' s P/S Range Over the Past 10 Years
Min: 0.43  Med: 1.76 Max: 2.99
Current: 2.46
0.43
2.99
PFCF 27.23
BRKR's PFCF is ranked lower than
54% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.85 vs. BRKR: 27.23 )
Ranked among companies with meaningful PFCF only.
BRKR' s PFCF Range Over the Past 10 Years
Min: 6.71  Med: 24.86 Max: 146.34
Current: 27.23
6.71
146.34
POCF 21.95
BRKR's POCF is ranked lower than
61% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.37 vs. BRKR: 21.95 )
Ranked among companies with meaningful POCF only.
BRKR' s POCF Range Over the Past 10 Years
Min: 4.24  Med: 19.18 Max: 50.83
Current: 21.95
4.24
50.83
EV-to-EBIT 23.93
BRKR's EV-to-EBIT is ranked lower than
63% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.96 vs. BRKR: 23.93 )
Ranked among companies with meaningful EV-to-EBIT only.
BRKR' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.2  Med: 19.50 Max: 36.2
Current: 23.93
5.2
36.2
EV-to-EBITDA 17.97
BRKR's EV-to-EBITDA is ranked lower than
66% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.01 vs. BRKR: 17.97 )
Ranked among companies with meaningful EV-to-EBITDA only.
BRKR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.7  Med: 16.50 Max: 36.2
Current: 17.97
4.7
36.2
Shiller P/E 46.71
BRKR's Shiller P/E is ranked lower than
60% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 43.43 vs. BRKR: 46.71 )
Ranked among companies with meaningful Shiller P/E only.
BRKR' s Shiller P/E Range Over the Past 10 Years
Min: 35.08  Med: 51.17 Max: 101.33
Current: 46.71
35.08
101.33
Current Ratio 2.26
BRKR's Current Ratio is ranked lower than
57% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.89 vs. BRKR: 2.26 )
Ranked among companies with meaningful Current Ratio only.
BRKR' s Current Ratio Range Over the Past 10 Years
Min: 1.26  Med: 2.12 Max: 4.99
Current: 2.26
1.26
4.99
Quick Ratio 1.41
BRKR's Quick Ratio is ranked lower than
74% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. BRKR: 1.41 )
Ranked among companies with meaningful Quick Ratio only.
BRKR' s Quick Ratio Range Over the Past 10 Years
Min: 0.43  Med: 1.27 Max: 3.95
Current: 1.41
0.43
3.95
Days Inventory 182.06
BRKR's Days Inventory is ranked lower than
80% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.32 vs. BRKR: 182.06 )
Ranked among companies with meaningful Days Inventory only.
BRKR' s Days Inventory Range Over the Past 10 Years
Min: 179.35  Med: 223.23 Max: 360.06
Current: 182.06
179.35
360.06
Days Sales Outstanding 51.77
BRKR's Days Sales Outstanding is ranked higher than
64% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.75 vs. BRKR: 51.77 )
Ranked among companies with meaningful Days Sales Outstanding only.
BRKR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.76  Med: 60.67 Max: 123.45
Current: 51.77
52.76
123.45
Days Payable 37.30
BRKR's Days Payable is ranked lower than
62% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.55 vs. BRKR: 37.30 )
Ranked among companies with meaningful Days Payable only.
BRKR' s Days Payable Range Over the Past 10 Years
Min: 26.4  Med: 29.93 Max: 147.25
Current: 37.3
26.4
147.25

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.33
BRKR's Dividend Yield is ranked lower than
93% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. BRKR: 0.33 )
Ranked among companies with meaningful Dividend Yield only.
BRKR' s Dividend Yield Range Over the Past 10 Years
Min: 0.14  Med: 0.15 Max: 0.33
Current: 0.33
0.14
0.33
Dividend Payout 0.06
BRKR's Dividend Payout is ranked higher than
98% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. BRKR: 0.06 )
Ranked among companies with meaningful Dividend Payout only.
BRKR' s Dividend Payout Range Over the Past 10 Years
Min: 0.29  Med: 0.29 Max: 0.29
Current: 0.06
Forward Dividend Yield 0.67
BRKR's Forward Dividend Yield is ranked lower than
79% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. BRKR: 0.67 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.33
BRKR's Yield on cost (5-Year) is ranked lower than
93% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.53 vs. BRKR: 0.33 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BRKR' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.14  Med: 0.15 Max: 0.33
Current: 0.33
0.14
0.33
3-Year Average Share Buyback Ratio 0.30
BRKR's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. BRKR: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BRKR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.1  Med: -6.00 Max: 0
Current: 0.3
-22.1
0

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 21.20
BRKR's Price/Net Current Asset Value is ranked lower than
80% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.06 vs. BRKR: 21.20 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BRKR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.43  Med: 12.30 Max: 103.75
Current: 21.2
2.43
103.75
Price/Tangible Book 7.92
BRKR's Price/Tangible Book is ranked lower than
72% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. BRKR: 7.92 )
Ranked among companies with meaningful Price/Tangible Book only.
BRKR' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.35  Med: 5.43 Max: 20.43
Current: 7.92
1.35
20.43
Price/Projected FCF 2.77
BRKR's Price/Projected FCF is ranked lower than
59% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.11 vs. BRKR: 2.77 )
Ranked among companies with meaningful Price/Projected FCF only.
BRKR' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.9  Med: 2.11 Max: 10.46
Current: 2.77
0.9
10.46
Price/Median PS Value 1.41
BRKR's Price/Median PS Value is ranked lower than
78% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. BRKR: 1.41 )
Ranked among companies with meaningful Price/Median PS Value only.
BRKR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.34  Med: 0.96 Max: 20.93
Current: 1.41
0.34
20.93
Price/Graham Number 3.50
BRKR's Price/Graham Number is ranked lower than
55% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. BRKR: 3.50 )
Ranked among companies with meaningful Price/Graham Number only.
BRKR' s Price/Graham Number Range Over the Past 10 Years
Min: 1.07  Med: 3.13 Max: 15.92
Current: 3.5
1.07
15.92
Earnings Yield (Greenblatt) (%) 4.15
BRKR's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. BRKR: 4.15 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BRKR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.8  Med: 5.10 Max: 19.4
Current: 4.15
2.8
19.4
Forward Rate of Return (Yacktman) (%) -0.90
BRKR's Forward Rate of Return (Yacktman) (%) is ranked lower than
71% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.32 vs. BRKR: -0.90 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BRKR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.2  Med: 9.40 Max: 110.4
Current: -0.9
-5.2
110.4

More Statistics

Revenue (TTM) (Mil) $1,646
EPS (TTM) $ 0.70
Beta0.88
Short Percentage of Float8.87%
52-Week Range $15.78 - 29.85
Shares Outstanding (Mil)161.45

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 1,699 1,753 1,824
EPS ($) 1.00 1.13 1.29
EPS w/o NRI ($) 1.00 1.13 1.29
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for BRKR

Headlines

Articles On GuruFocus.com
Largest Insiders' Trades of the Week Jun 10 2016 
Mariko Gordon Nearly Doubles Stake in Forward Air Jan 04 2016 
Mariko Gordon Acquires Five New Stakes in Second Quarter Aug 27 2015 
Insiders New Buys: Bruker Corp Jun 22 2015 
Weekly CEO Buys Highlight: BRKR, GAIN, LUB, NUVA, FGP Jun 21 2015 
Weekly CEO Buys Highlight: NGL, BRKR, UTHR, KTOS, GBL Dec 24 2012 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 10,000 Shares Mar 17 2011 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 1,220 Shares Mar 03 2011 
Weekly CEO Buys Highlight: Deer Consumer Products, Dynex Capital, Bruker BioSciences Corp, American Mar 27 2010 
Weekly CEO Buys Highlight: Bruker BioSciences Corp, Dynex Capital Inc, American Dairy Inc, Pioneer D Mar 21 2010 

More From Other Websites
Bruker Introduces New Generation of EBSD Detectors and Software for Advanced Post-Processing and... Jul 25 2016
Bruker Introduces New Generation of EBSD Detectors and Software for Advanced Post-Processing and... Jul 25 2016
Zacks.com featured highlights: NVIDIA, Bruker, Trupanion, Masimo and Laredo Petroleum Jul 22 2016
Bruker Announces Date and Time of Second Quarter 2016 Earnings Release and Webcast Jul 18 2016
Leading Logic and Foundry Manufacturers Select Bruker X-Ray Metrology Tools Jul 12 2016
Leading Logic and Foundry Manufacturers Select Bruker X-Ray Metrology Tools Jul 12 2016
Zacks.com featured highlights: DeVry Education Group, Herbalife, Children's Place, Bruker and... Jul 07 2016
5 Liquid Stocks to Enhance Your Portfolio Return Jul 06 2016
Research Report Initiated on Select Healthcare Equities Jul 01 2016
5 Stocks to Buy on Stronger GDP Data Jun 29 2016
Bruker Poised on Product Launches amid Near-Term Risks Jun 29 2016
Bruker Announces More Comprehensive and Efficient NMR Profiling Module for Detailed Lipoprotein... Jun 28 2016
Bruker Acquires Software Assets for Next-Generation Automated and Quantitative Mineral... Jun 20 2016
Bruker Acquires Software Assets for Next-Generation Automated and Quantitative Mineral... Jun 20 2016
Bruker Collaborates with CDC to Advance Infectious Disease Surveillance Jun 16 2016
Bruker Collaborates with CDC to Advance Infectious Disease Surveillance Jun 16 2016
Bruker Well Poised on Product Innovation amid Currency Woes Jun 15 2016
Bruker Shows Innovative rapifleX MALDI-TOF/TOF at ASMS 2016 Jun 06 2016
Bruker Launches rapifleX MALDI PharmaPulse Solution for uHTS Jun 06 2016
Bruker Introduces Innovative timsTOF™ Mass Spectrometer Jun 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)